NO159800C - Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e. - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e.

Info

Publication number
NO159800C
NO159800C NO841465A NO841465A NO159800C NO 159800 C NO159800 C NO 159800C NO 841465 A NO841465 A NO 841465A NO 841465 A NO841465 A NO 841465A NO 159800 C NO159800 C NO 159800C
Authority
NO
Norway
Prior art keywords
spiroxanes
analogue
preparation
therapeutically active
open ring
Prior art date
Application number
NO841465A
Other languages
English (en)
Norwegian (no)
Other versions
NO841465L (no
NO159800B (no
Inventor
Juergen Grob
Jaroslav Kalvoda
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO841465L publication Critical patent/NO841465L/no
Publication of NO159800B publication Critical patent/NO159800B/no
Publication of NO159800C publication Critical patent/NO159800C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO841465A 1983-04-13 1984-04-12 Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e. NO159800C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (3)

Publication Number Publication Date
NO841465L NO841465L (no) 1984-10-15
NO159800B NO159800B (no) 1988-10-31
NO159800C true NO159800C (no) 1989-02-08

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO841465A NO159800C (no) 1983-04-13 1984-04-12 Analogifremgangsmaate til fremstilling av terapeutisk aktive 20-spiroksaner og analoge med aapnet ring e.

Country Status (23)

Country Link
US (1) US4559332A (enExample)
EP (1) EP0122232B1 (enExample)
JP (1) JPS59231100A (enExample)
AR (4) AR241918A1 (enExample)
AT (1) ATE39256T1 (enExample)
AU (1) AU565017B2 (enExample)
CA (1) CA1220781A (enExample)
DD (2) DD251144A5 (enExample)
DE (2) DE3475622D1 (enExample)
DK (1) DK163988C (enExample)
ES (4) ES8602846A1 (enExample)
FI (1) FI77669C (enExample)
GR (1) GR81834B (enExample)
HU (1) HU191406B (enExample)
IE (1) IE57541B1 (enExample)
IL (1) IL71504A (enExample)
LU (1) LU91072I2 (enExample)
NL (1) NL300144I2 (enExample)
NO (1) NO159800C (enExample)
NZ (1) NZ207826A (enExample)
PH (1) PH19997A (enExample)
PT (1) PT78413B (enExample)
ZA (1) ZA842710B (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
US5248807A (en) * 1991-01-29 1993-09-28 Shionogi & Co., Ltd. Triterpene derivatives
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
EP1167380A3 (en) * 1995-12-11 2004-12-08 G.D. Searle & Co. 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
WO1997021720A2 (en) 1995-12-11 1997-06-19 G.D. Searle And Co. Processes for preparation of 7 alpha-carboxyl 9,11-epoxy steroids and intermediates useful therein and a general process for the epoxidation of olifinic double bonds
EP1148061B1 (en) * 1996-12-11 2007-10-17 G.D. Searle LLC. Epoxidation process
NZ336004A (en) 1996-12-11 2001-04-27 G Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
ZA9711038B (en) * 1996-12-11 1999-01-25 Searle & Co Spr process for preparation of 9,11-Epoxy steroids and intermediates useful therein
CA2298453A1 (en) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Process for producing seasoning liquors with flavor of vegetables pickled in salted rice bran paste
HUP0104249A3 (en) * 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EA004877B1 (ru) 1998-12-23 2004-08-26 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
AU3103800A (en) * 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
DE69911058T2 (de) * 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
BR9916486A (pt) 1998-12-23 2002-02-05 Searle Llc Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
DK1140189T3 (da) * 1998-12-23 2003-09-15 Searle Llc Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
US6458850B1 (en) * 1998-12-23 2002-10-01 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
CN1152886C (zh) * 1999-12-08 2004-06-09 法马西亚公司 表现出溶解速度加快的依匹乐酮晶形
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
WO2001041770A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Nanoparticulate eplerenone compositions
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US20040235809A1 (en) * 2000-07-27 2004-11-25 Alexander John C Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
WO2002046386A2 (en) * 2000-10-30 2002-06-13 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
DE60129838T2 (de) * 2000-11-09 2008-04-30 Astrazeneca Ab Orale pharmazeutische zusammensetzung mit einem blockcopolymer
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
KR20040107481A (ko) * 2002-03-18 2004-12-20 파마시아 코포레이션 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
MXPA04009033A (es) * 2002-03-18 2005-01-25 Pharmacia Corp Combinacion de un antagonista de receptor de aldosterona y acido nicotinico o un derivado de acido nicotinico.
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
EP1487859B1 (en) * 2002-03-22 2008-08-13 Pharmacia & Upjohn Company LLC Process to prepare eplerenone
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
DE60308388T2 (de) * 2002-08-16 2007-09-20 Pharmacia & Upjohn Co. Llc, Kalamazoo 5-Androsten-3beta-ol-Steroide und Verfahren für ihre Herstellung
US7196208B2 (en) * 2002-11-06 2007-03-27 Peter Guillaume Marie Wuts Processes for preparing 7-carboxy substituted steroids
RS20050339A (sr) * 2002-11-07 2007-08-03 Pharmacia & Upjohn Company Llc., Postupci za dobijanje c-7 supstituisanih 5-androstena
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CN1934126A (zh) * 2004-03-22 2007-03-21 法玛西雅厄普约翰有限责任公司 9,11环氧甾族化合物的改进制备方法
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
WO2008074098A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
ES544770A0 (es) 1987-05-01
DD251144A5 (de) 1987-11-04
AU565017B2 (en) 1987-09-03
FI841400A0 (fi) 1984-04-09
FI77669C (fi) 1989-04-10
NO841465L (no) 1984-10-15
PH19997A (en) 1986-08-28
ES8705459A1 (es) 1987-05-01
IE57541B1 (en) 1992-10-07
JPS59231100A (ja) 1984-12-25
FI77669B (fi) 1988-12-30
CA1220781A (en) 1987-04-21
IL71504A (en) 1987-07-31
AU2685384A (en) 1984-10-18
NZ207826A (en) 1986-07-11
AR242221A1 (es) 1993-03-31
DK163988C (da) 1992-09-21
DE3475622D1 (en) 1989-01-19
PT78413A (en) 1984-05-01
NO159800B (no) 1988-10-31
DK163988B (da) 1992-04-27
EP0122232A1 (de) 1984-10-17
ES544768A0 (es) 1987-05-01
NL300144I1 (nl) 2004-06-01
NL300144I2 (nl) 2004-06-01
EP0122232B1 (de) 1988-12-14
ES531517A0 (es) 1985-12-01
AR242223A1 (es) 1993-03-31
DE122004000012I2 (de) 2006-06-08
GR81834B (enExample) 1984-12-12
ES8705460A1 (es) 1987-05-01
ES544769A0 (es) 1987-05-01
US4559332A (en) 1985-12-17
DK189484D0 (da) 1984-04-12
FI841400L (fi) 1984-10-14
PT78413B (en) 1986-08-22
AR241918A1 (es) 1993-01-29
JPH0212479B2 (enExample) 1990-03-20
IL71504A0 (en) 1984-07-31
DK189484A (da) 1984-10-14
HU191406B (en) 1987-02-27
DE122004000012I1 (de) 2012-05-16
ES8705461A1 (es) 1987-05-01
ES8602846A1 (es) 1985-12-01
ZA842710B (en) 1984-11-28
ATE39256T1 (de) 1988-12-15
LU91072I2 (fr) 2004-04-07
DD233375A5 (de) 1986-02-26
AR242222A1 (es) 1993-03-31
IE840906L (en) 1984-10-13

Similar Documents

Publication Publication Date Title
NO841465L (no) 20-spiroksaner og analoge med aapnet ring e, fremgangsmaate til deres fremstilling samt farmasoeytiske preparater herav
NO841703L (no) Fremgangsmaate til fremstilling av n-alkylerte dipeptider og deres estere.
NO157738C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzoksazinoner og benzoksazolinoner.
NO161317C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oksikamer.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NO871028D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazol- og oksazol-derivater.
NO158460C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO159930C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indeno-pyridazinon-derivater.
NO158417C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive urinstoffer og tiourinstoffer.
NO162860C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzo-(pyrano og tiopyrano)-pyridiner.
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
NO159929C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive n-substituerte 2-pyridylindoler.
NO167808C (no) Fremgangsmaate til fremstilling av n-alkylerte dipeptider og deres estere.
NO851452L (no) Fremgangsmaate og cellelinje for fremstilling av plasminogene aktivatorer.
NO163570C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acylaminomitosaner.
NO165493C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolindioner og pyridopyrimidindioner.
NO159924C (no) Fremgangsmaate for fremstilling av sement og innretning for utfoerelse av fremgangsmaaten.
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
NO802277L (no) Fremgangsmaate til fremstilling av terapeutisk aktive 25-halocholest-5-en-3beta,22-dioler og estere derav
NO881713L (no) Fremgangsmaate for fremstilling av di-t-butylfenyl-alkyl og benzylethere.
NO166726C (no) Fremgangsmaate for fremstilling av arylglycidyletere og 3-substituerte 1-alkylamino-2-propanoler.
NO882335D0 (no) Fremgangsmaate for fremstilling av 5-(omega-ammonio-acyloksy-metylen)-tetrahydrofuraner og -tetrahydrotiofener.
NO159183C (no) Fremgangsmaate for fremstilling av lenser og liknende.
NO163617C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolidinon-derivater.
NO162964C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyridinderivater.

Legal Events

Date Code Title Description
MK1K Patent expired